| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,556,000 |
| Market
Cap: |
2.00(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.77 - $40 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
13,677 |
358,480 |
482,823 |
| Total Sell Value |
$0 |
$542,205 |
$13,057,890 |
$17,149,631 |
| Total People Sold |
0 |
2 |
7 |
8 |
| Total Sell Transactions |
0 |
4 |
13 |
24 |
| End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Khattar Jack A. |
President, CEO |
• • – |
2025-04-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(16,850) |
1,005,600 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,850 |
1,008,683 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-03-10 |
4 |
D |
$32.06 |
$538,768 |
D/D |
(16,805) |
991,833 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
1,008,638 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-03-10 |
4 |
D |
$32.06 |
$64,665 |
D/D |
(2,017) |
12,681 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,800 |
13,636 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-03-07 |
4 |
D |
$39.11 |
$53,033 |
D/D |
(1,356) |
15,151 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,625 |
16,507 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-03-07 |
4 |
D |
$39.11 |
$726,703 |
D/D |
(18,581) |
973,638 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2025-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,640 |
992,219 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-03-05 |
4 |
D |
$33.05 |
$62,531 |
D/D |
(1,892) |
13,882 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-03-05 |
4 |
D |
$33.05 |
$105,529 |
D/D |
(3,193) |
10,898 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2025-03-05 |
4 |
D |
$33.05 |
$49,079 |
D/D |
(1,485) |
12,704 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2025-03-05 |
4 |
D |
$33.05 |
$48,517 |
D/D |
(1,468) |
9,635 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-02-26 |
4 |
D |
$39.48 |
$113,900 |
D/D |
(2,885) |
15,774 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,760 |
17,683 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
14,091 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
12,899 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2025-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
14,189 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2025-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
11,103 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
11,591 |
|
- |
|
| Gemayel Georges |
Director |
– • – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,369 |
18,684 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
11,024 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
12,939 |
|
- |
|
| Newhall Charles W III |
Director |
– • – |
2025-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,369 |
135,644 |
|
- |
|
379 Records found
|
|
Page 1 of 16 |
|
|
0.44 (1.37%) 
